Histogen's Hair Stimulating Complex (HSC) is a proprietary liquid formula created by the culturing of newborn cells in a simulated embryonic environment of suspension and very low oxygen, and then harvesting the naturally secreted growth factors, proteins and other synergistic bioproducts that are produced.

HSC is currently being developed and evaluated as an injectable for hair growth. The embryonic-like proteins and growth factors within the complex, including follistatin, VEGF and KGF, have been shown to both stimulate resting hair follicles to produce new hair, as well as induce stem cells in the scalp to form new follicles.

HSC Clinical Development
The pilot 24 subject clinical trial of HSC was a double-blind, placebo-controlled evaluation of safety in the clinical application of the product as an injectable for hair growth. Quantitative analysis of clinical macrophotography and subject biopsies were utilized to evaluate treatment safety and efficacy. No adverse events were seen at any timepoint, including the two year follow-up.

HSC also achieved statistically significant efficacy at both the 12 week and 1 year timepoints, including increases in hair count, hair thickness, and hair density. This represents the first time that a single application of a treatment has produced this type of significant hair growth in a human study.

Comprehensive results from this first-in-man clinical trial of HSC were published in the peer-reviewed Journal of Drugs in Dermatology in November 2011:
http://jddonline.com/articles/dermatology/1650

Enrollment of 55 patients with male pattern hair loss in the Phase I/II clinical trial of HSC in Manila, Philippines has been completed and the trial is ongoing. HSC continues to advance, and Histogen looks forward to sharing further details as the product and clinical trials progress. Clinical evaluation of HSC is required to fully examine product safety, efficacy and treatment specifications prior to regulatory submission in any country.

Hair Growth Market
The hair loss market is both large and underserved, affecting over 40 million men and 21 million women in the United States alone, but with less than 7% of sufferers currently seek treatment due to the limitations of available options. HSC represents a potentially revolutionary new injectable treatment for the millions suffering from hair loss, offering benefits over daily-use, limited efficacy prescription products as well as invasive surgical treatments.